According to Precigen's latest financial reports the company's current revenue (TTM) is $6.22 M. In 2022 the company made a revenue of $26.9 M a decrease over the years 2021 revenue that were of $55.88 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $6.22 M | -76.87% |
2022 | $26.9 M | -51.85% |
2021 | $55.88 M | -45.84% |
2020 | $0.10 B | 25.71% |
2019 | $82.07 M | -48.88% |
2018 | $0.16 B | -30.55% |
2017 | $0.23 B | 21.11% |
2016 | $0.19 B | 9.98% |
2015 | $0.17 B | 141.35% |
2014 | $71.93 M | 206.25% |
2013 | $23.48 M | 68.67% |
2012 | $13.92 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Organovo ONVO | $0.24 M | -96.11% | ๐บ๐ธ USA |
Orchard Therapeutics
ORTX | $21.83 M | 250.83% | ๐ฌ๐ง UK |
Novavax NVAX | $0.69 B | 11,039.94% | ๐บ๐ธ USA |
Novocure
NVCR | $0.50 B | 8,082.14% | Jersey |